SPOTLIGHT: Toyama seeks early flu pact


Japan's Toyama Chemical is looking to do a development and marketing rights deal on a promising, early-stage bird flu therapy in order to gin up some revenue. Any pact prior to proof-of-concept is likely to go at a discount. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.